$57.10▲ 0.20 (0.35%)
Real-time prices · US MarketsHigh-quality business with 39% return on equity and 15% profit margins.
cautious analyst consensus — few Buy ratings.
Quality
9.2
Health
5.5
Growth
5.8
Valuation
6.7
Sentiment
5.2
Analyst Target
$63.08
▲ +10.5% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
16.0×
price-to-earnings
Forward P/E
9.3×
next 12 months est.
Market Cap
$116.6B
market capitalization
Div Yield
4.43%
dividend yield
Profit Margin
15.0%
net profit margin
Gross Margin
72.0%
revenue minus COGS
ROE
38.7%
return on equity
Beta
0.24
vs S&P 500
52-Week Range
$43 — $63
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Bristol-Myers Squibb Company right now?
Bristol-Myers Squibb Company's Q·Score is 6.7/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 39% return on equity and 15% profit margins. Key area to monitor: cautious analyst consensus — few Buy ratings. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for BMY?
The consensus price target for BMY is $63.08, based on ratings from 25 Wall Street analysts. This is 10.5% above the current price of $57.10. Price targets are forward-looking estimates and not guarantees of future performance.
Is BMY overvalued or undervalued?
Bristol-Myers Squibb Company (BMY) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 9.3×. The consensus analyst price target of $63.08 is 10% above the current price.
When does Bristol-Myers Squibb Company report its next earnings?
Bristol-Myers Squibb Company's next earnings report is expected on approximately July 30, 2026.
What is Bristol-Myers Squibb Company's profit margin?
Bristol-Myers Squibb Company has a net profit margin of 15.0%, which is solid for most industries. Its gross margin stands at 72.0%, indicating a high-margin business model.
What is BMY's dividend yield?
Bristol-Myers Squibb Company currently offers a dividend yield of 4.43%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.
Is Bristol-Myers Squibb Company's revenue growing?
Bristol-Myers Squibb Company is reporting modest revenue growth of 2.6%. Earnings are also growing at 9.2%, indicating improving profitability.
How much debt does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb Company has a debt-to-equity ratio of 2.31×, reflecting a high debt-to-equity ratio, which increases financial risk especially in rising rate environments. Its current ratio is 1.42×, suggesting it should be monitored for near-term liquidity.
Compare BMY with any stock